Skip to main content

Table 3 Estimation of NS5A and NS5B properties by “protparam”

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

PROTPARAM NS5A 1a NS5A 3a NS5B 1a NS5B 3a
Number of amino acids 229 233 591 591
Molecular weight 25,637.51 25,565.16 65,311.27 66,134.92
Theoretical pI 8.34 7.53 9.12 9.02
Estimated half-life 1.9 h (mammalian reticulocytes, in vitro) 1.9 h (mammalian reticulocytes, in vitro) 1.9 h (mammalian reticulocytes, in vitro) 1.9 h (mammalian reticulocytes, in vitro)
 > 20 h (yeast, in vivo)  > 20 h (yeast, in vivo)  > 20 h (yeast, in vivo)  > 20 h (yeast, in vivo)
 > 10 h (Escherichia coli, in vivo)  > 10 h (Escherichia coli, in vivo)  > 10 h (Escherichia coli, in vivo)  > 10 h (Escherichia coli, in vivo)
Instability index Unstable
45.71
Unstable
44.48
Unstable
41.41
Unstable
45.66
Aliphatic index 70.66 69.53 86.7 85.37
GRAVY  − 0.262  − 0.226  − 0.103  − 0.219
  1. Almost both genotypes showed similar features. However, there were significant differences between pI of NS5S 1a and 3a genotypes